Bob Davis

Bob Davis invests as a partner at HCP (Highland Capital Partners) and angel-invests from Boston, writing $100k-$250k checks at seed and Series A in digital health and medical devices, with no AI flag. His Highland affiliation gives him institutional credibility, and the personal angel check size suggests selective conviction-led investing alongside fund activity. Founders building Boston-area digital health companies, medical devices with clear clinical and reimbursement pathways, or platforms that benefit from a senior East Coast investor on the cap table are the natural fit. The absence of an AI flag suggests he evaluates companies on traditional healthcare fundamentals (clinical evidence, payor strategy, regulatory clarity) rather than AI-defensibility narratives. He is the wrong audience for AI-heavy plays where the AI is the thesis, biotech, or consumer wellness without a clinical angle. The check size is meaningful and a yes from him often pulls other quality East Coast capital. Outreach via LinkedIn is viable, but warm introductions through Highland portfolio CEOs, MassBio, or the broader Boston healthcare operator community will materially outperform cold outreach. Diligence will be metrics and clinical-evidence fluent, so come with traction, payor relationships, and regulatory plans rather than vision narratives. Without an explicit thesis statement attached, founders should treat his Highland portfolio as the primary signal of taste and fit.